- Home
- Publications
- Publication Search
- Publication Details
Title
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 16, Issue 7, Pages 16414-16439
Publisher
MDPI AG
Online
2015-07-20
DOI
10.3390/ijms160716414
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis
- (2015) Honggang Wang et al. IMMUNOLOGY
- Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis
- (2015) Michael J. Turner et al. JOURNAL OF NEUROIMMUNOLOGY
- Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
- (2015) Eva Havrdova et al. Therapeutic Advances in Neurological Disorders
- Long-term efficacy of alemtuzumab in polymyositis
- (2015) Tobias Ruck et al. RHEUMATOLOGY
- No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis
- (2014) Richard Nixon et al. ADVANCES IN THERAPY
- Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety
- (2014) David E Jones et al. Expert Review of Clinical Immunology
- Release from Regulatory T Cell-Mediated Suppression during the Onset of Tissue-Specific Autoimmunity Is Associated with Elevated IL-21
- (2014) L. E. Clough et al. JOURNAL OF IMMUNOLOGY
- Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
- (2014) O. Tuohy et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
- (2014) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity
- (2014) O. Kousin-Ezewu et al. NEUROLOGY
- Alemtuzumab: The advantages and challenges of a novel therapy in MS
- (2014) T. Menge et al. NEUROLOGY
- Isolation of Primary Murine Brain Microvascular Endothelial Cells
- (2014) Tobias Ruck et al. Jove-Journal of Visualized Experiments
- Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis
- (2013) Gilbert H. Daniels et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
- (2013) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Immune status following alemtuzumab treatment in human CD52 transgenic mice
- (2013) Michael J. Turner et al. JOURNAL OF NEUROIMMUNOLOGY
- Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
- (2013) L. Azzopardi et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10
- (2013) Esther Bandala-Sanchez et al. NATURE IMMUNOLOGY
- Reprogramming the immune repertoire with alemtuzumab in MS
- (2013) Heinz Wiendl et al. Nature Reviews Neurology
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Asymmetric thymocyte death underlies the CD4:CD8 T-cell ratio in the adaptive immune system
- (2013) C. Sinclair et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
- (2013) J. L. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
- (2012) M. D. Cossburn et al. NEUROLOGY
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis
- (2012) Sambasiva P. Rao et al. PLoS One
- Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients
- (2012) R. A. Clark et al. Science Translational Medicine
- Immune mechanisms of new therapeutic strategies in multiple sclerosis—A focus on alemtuzumab
- (2011) Luisa Klotz et al. CLINICAL IMMUNOLOGY
- CD4+FOXP3+ T Regulatory Cells in Human Autoimmunity: More Than a Numbers Game
- (2011) S. A. Long et al. JOURNAL OF IMMUNOLOGY
- Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
- (2011) Alasdair J Coles et al. LANCET NEUROLOGY
- HLA-DRB1*15:01 and multiple sclerosis: a female association?
- (2011) Haritz Irizar et al. Multiple Sclerosis Journal
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
- (2011) M. Cossburn et al. NEUROLOGY
- Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
- (2010) Joanne L. Jones et al. BRAIN
- Acute infusion reactions induced by monoclonal antibody therapy
- (2010) Enrico Maggi et al. Expert Review of Clinical Immunology
- A Novel Strategy To Reduce the Immunogenicity of Biological Therapies
- (2010) J. Somerfield et al. JOURNAL OF IMMUNOLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
- (2009) M. C. Dalakas et al. BRAIN
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- Clustering and commonalities among autoimmune diseases
- (2009) Ian R. Mackay JOURNAL OF AUTOIMMUNITY
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- (2009) Sara A. J. Thompson et al. JOURNAL OF CLINICAL IMMUNOLOGY
- IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
- (2009) Joanne L. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells
- (2009) Martin Guimond et al. NATURE IMMUNOLOGY
- CD4+CD25+FOXP3+Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath-1H
- (2008) D. D. Bloom et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Activation of myelin reactive T cells in multiple sclerosis: A possible role for T cell degeneracy?
- (2008) Piet Stinissen et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-21 and TGF-β are required for differentiation of human TH17 cells
- (2008) Li Yang et al. NATURE
- Anti–Glomerular Basement Membrane Disease after Alemtuzumab
- (2008) Menna R. Clatworthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation